Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

SHANGHAI and HONG KONG, March 3, 2026 /PRNewswire/ -- Hua Medicine (the Company, Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GK… [+12138 chars]
Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China - FHMnews